2016-03-30 16:03:04 UTC

GI & Hepatology News Reports on Recent PPI, Dementia Study

March 30, 2016

Last month AGA released tips on how to talk to your patients about proton pump inhibitor use and dementia following the study release.

A widely discussed study, published in JAMA Neurology last month, reported that long-term Proton Pump Inhibitor Use was linked to increased dementia risk. GI & Hepatology News recently reported on the study findings, which note that "overall, the risk of incident dementia was 44 percent higher among the 2,950 patients who received regular proton pump inhibitors, compared with 70,729 who didn’t receive PPIs (hazard ratio of 1.44)." 

Last month AGA released tips on how to talk to your patients about PPIs and dementia following the study release, and cautions that it focuses on long-term users. Clinicians should recognize that PPIs are highly effective in treating acid-related disorders and few hard indications for long-term PPI use, the post adds.

In the study, led by Willy Gomm, PhD, of the German Center for Neurodegenerative Diseases, Bonn, researchers reviewed data from a German insurance database from 2004-2011. The study population included more than 70,000 adults aged 75 years and older who did not have dementia at the beginning of the study trial. Gomm and colleagues found that the risk of dementia was not significantly different based on specific drug in a subgroup analysis of the three most often prescribed PPIs, omeprazole, pantoprazole, and esomeprazole.

GI & Hepatology News points out that there are limitations to the study, and that researchers can only provide a statistical association between PPI use and risk of dementia. 

Read the full GI & Hepatology News report and AGA post


More on Barrett's Esophagus

Porcine Esophageal Submucosal Gland Culture Model Shows Capacity for Proliferation and Differentiation

Oct. 22, 2017

We describe a novel porcine 3-dimensional culture model that reproduces esophageal submucosal gland proliferation in vivo associated with cancer and injury.

Late Recurrence of Barrett’s Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report From Ablation in Intestinal Metaplasia Containing Dysplasia Trial

Sept. 1, 2017

Endoscopic surveillance of patients with BE treated with radiofrequency ablation will likely be of diminishing value as the time since ablation grows.

Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett’s Esophagus With a Minimally Invasive Cell Sampling Device

Sept. 1, 2017

We found Cytosponge screening with endoscopic confirmation to be a cost-effective strategy.